Related Experiment Videos
[Sensitivity to cephalosporins of coagulase-negative methicillin-resistant staphylococci. In vitro studies by
Abstract:
The activity of five cephalosporins has been studied with 80 coagulase-negative methicillin-resistant Staphylococcus strains (SCN meti-R) isolated from hospitalized patients. It has been evaluated in vitro under different conditions, in liquid as well as solid media. Results show that in all cases cefamandole has the highest activity on SCN meti-R. Thus cefamandole is quite effective for the prophylaxis of Staphylococcal infections. Furthermore the association of cefamandole with other antibiotics should be tested as an alternative to vancomycin for the treatment of SCN meti-R severe infections.
Insights
Cefamandole demonstrates high activity against coagulase-negative methicillin-resistant Staphylococcus strains (SCN meti-R). This suggests its effectiveness for preventing staphylococcal infections and potential use in combination therapy for severe infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Coagulase-negative methicillin-resistant Staphylococcus (SCN meti-R) poses a significant threat in hospital settings.
- Effective treatment options for SCN meti-R infections are crucial due to rising antibiotic resistance.
Purpose of the Study:
- To evaluate the in vitro activity of five cephalosporins against SCN meti-R strains.
- To identify cephalosporins with potent activity for potential therapeutic applications.
Main Methods:
- In vitro susceptibility testing of five cephalosporins against 80 SCN meti-R strains.
- Evaluation conducted in both liquid and solid media under various conditions.
Main Results:
- Cefamandole exhibited the highest antimicrobial activity against all tested SCN meti-R strains.
- Cefamandole proved effective in inhibiting SCN meti-R growth in vitro.
Conclusions:
- Cefamandole is a promising agent for the prophylaxis of staphylococcal infections.
- Further research into combination therapy with cefamandole may offer an alternative to vancomycin for severe SCN meti-R infections.